About Caphosol

Start With Caphosol® and Stay on Top of the Risk

Oral mucositis (OM) can interfere with treatment-causing dose reductions and delays.2

Caphosol® (supersaturated calcium phosphate rinse) is indicated for dryness of the mouth or throat (hyposalivation, xerostomia), regardless of the cause and regardless of whether the conditions are temporary or permanent.

Caphosol is also indicated as an adjunct to standard oral care in treating the mucositis that may be caused by radiation or high dose chemotherapy.

Start Caphosol when cancer treatment starts: the submucosa is damaged before any clinical signs of erythema or ulceration are apparent.1

As OM severity increases, rates of significant infection, total parenteral nutrition, days in hospital, hospital charges, and mortality rates increase.3

Caphosol Can Change the Picture

In a randomized, double-blind, placebo-controlled trial, Caphosol was shown to:15

  • Reduce the incidence, duration, and severity of OM compared with control
    • 49% reduction in days of mucositis
    • 63% decrease in duration of pain
  • Reduce morphine use by 72%



US Pack Shot

EUSAPharma Caphosol
® Caphosol is a registered trademark of EUSA Pharma.